Work

Abstract CT236: Randomized, double-blind, placebo-controlled trial of preventative MUC1 vaccine in patients with newly diagnosed advanced adenomas: Results from one-year booster

Year: 2019

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2019-ct236

Authors: Olivera J. Finn, Lisa Boardman, Marcia Cruz-Correa, Ajay Bansal, David Kastenberg, Chin Hurr, Sharon Kaufman, Colleen Akerley, Lynda Dzubinski, April Felt, Karrie Fursa, L.M. Rodriguez, Ellen Richmond, Asad Umar, Eva Szabo, John McKolanis, Ryan McMurray, Nathan Foster, Andres Salazar, Paul Limburg, Robert Schoen

Institutions: University of Pittsburgh, Mayo Clinic, University of Puerto Rico System, University of Kansas Medical Center, Thomas Jefferson University, Massachusetts General Hospital, National Cancer Institute, Uniformed Services University of the Health Sciences, Oncovir (United States)

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2953820709

Cites:

Cited by: 7

Related to: 7